Indication
Xylistin is indicated for the treatment of acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly indicated in the infection caused by sensitive strains of Pseudomonas aerouginosa. Xylistin is not indicated for infections due to Proteus or Neisseria. Xylistin is very effective in the treatment of infections due to the following gram-negative organisms : Enterobacter aerogenes, E. coli, Klebsiella pneumonia and Pseudomonas aeruginosa.
Dosage and Administration
Route of Administration: Intravenous or Intramuscular.
Reconstitution for Intravenous or Intramuscular administration: Each vial should be reconstituted with 2 ml normal saline. The reconstituted solution provides Colistimethate Sodium at a concentration equivalent to 75 mg /ml Colistin. During reconstitution swirl gently to avoid frothing.
The dose of Colistin should be 2.5 to 5 mg/kg per day of Colistin base in 2 to 4 divided doses for patients with normal renal function, depending on the severity of the infection. A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued for up to 12 days. In obese individuals, dosage should be based on ideal body weight. The daily dose and frequency should be reduced for the patients with renal impairment.
OR, AS DIRECTED BY PHYSICIAN.
Composition
Xylistin 150: Each vial contains Colistimethate Sodium USP equivalent to 150 mg Colistin.